The Price of Acquisitions: How Big Pharma’s Big Purchases Can Mean Big Bills for Your Health
<p>Healthcare, a fundamental human right, shouldn’t feel like a luxury cruise line — exorbitant price tag and all. Yet, this is the reality for many, thanks in part to the astronomical costs of new drugs. The pharmaceutical industry, a relentless engine of innovation, churns out life-saving (and life-changing) medications, but at a price that often leaves patients gasping for air. And we’re forced to ask: <strong>are we paying too much for a healthy future?</strong></p>
<p>GSK will buy asthma drug developers for up to $1.4 billion in a pipeline push. GSK’s acquisition comes as the British firm seeks to boost its pipeline to keep up with rivals amid a flurry of deals in the pharmaceutical sector that has seen top drugmakers seeking to cash in on fast-paced developments in medical sciences by snapping up innovative biotechs. Significant deals include Bristol Myers Squibb’s <a href="https://www.marketwatch.com/investing/stock/BMY?mod=MW_story_quote" rel="noopener ugc nofollow" target="_blank">BMY, -0.84%</a> $14 billion acquisition of Karuna Therapeutics. Those deals have to be paid for.</p>
<p><a href="https://richardameyer.medium.com/the-price-of-acquisitions-how-big-pharmas-big-purchases-can-mean-big-bills-for-your-health-ed3139d160f3"><strong>Click Here</strong></a></p>